Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy
- Registration Number
- NCT00951132
- Lead Sponsor
- University Hospital, Akershus
- Brief Summary
The purpose of this study is to investigate whether rosuvastatin decreases measures of inflammation in depressive patients.
- Detailed Description
Depression is associated with increased risk of cardiovascular disease, in which one possible mechanism is systemic inflammation. Further, patients at high risk of cardiovascular disease, rosuvastatin decreases the risk, especially among patients with increased inflammation. This is a proof-of-concept study to investigate whether the antiinflammatory effect of rosuvastatin is similar in depressive as in patients with cardiovascular disease.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Persisting self-reported depressive symptoms > 5 weeks
- Indications of aortic atherosclerosis on PET/CT
Exclusion Criteria
- Clinical indication of statin use.
- Contraindication of statins, or of PET/CT and MRI.
- Established cardiovascular disease.
- Bipolar disorder og comorbid psychosis.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Placebo Placebo 2 rosuvastatin Rosuvastatin
- Primary Outcome Measures
Name Time Method Mean SUV of large arteries 3 months
- Secondary Outcome Measures
Name Time Method Peripheral endothelial function (pulse wave amplitude) 3 months Circulatory proinflammatory markers 3 months Heart rate variability 3 months Depressive symptoms 3 months
Trial Locations
- Locations (1)
Akershus University Hospital
🇳🇴Lorenskog, Akershus, Norway